Chemotherapy of hormonorefractory and hormonoresistant metastatic prostate cancer;Chimiothérapies du cancer de prostate métastatique hormonoréfractaire ou hormonorésistant

Progres en Urologie

Volumn 18, Issue SUPPL. 7, 2008, Pages

  Timsit, M O ^a,b   Lebret, T ^c   Mejean A ^a,b  

^a LIPADE   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c FOCH HOSPITAL   (France)

Author keywords

Anti angigenic; Chemotherapy; Docetaxel; Hormon refractory prostate cancer; Prostate carcinoma; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DOCETAXEL; TAXOID;

ARTICLE; DRUG RESISTANCE; HUMAN; MALE; METASTASIS; PATHOLOGY; PROSTATE TUMOR;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 57349138446     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1166-7087(08)74568-8     Document Type: Article

References (63)

1. Nelson W.G., Saad F., Debruyne F.M.J., et al. New therapeutic targets and treatments for metastatic prostate cancer. In Prostate cancer, 6th International consultation. Saad Khouty 6 (2006) 311-344
2. Recommandation 2007 de l'AFU en onco-urologie. Prog Urol 2007;17:1159-230.
3. Heindenreich A., Aus G., Abbou C.C., et al. Guidelines on prostate cancer. Guidelines de l'EAU (2008)
4. Basch E.M., Somerfield M.R., Beer T.M., Carducci M.A., Higano C.S., Hussain M.H., and Scher H.I. American Society of Clinical Oncology American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castrationresistant) prostate cancer. J Clin Oncol 25 33 (2007) 5313-5318
5. Tannock I.F., Osoba D., Stockler M.R., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14 (1996) 1756-1764
6. Yagoda A. Cytotoxic agents in prostate cancer: an enigma. Semin Urol 1 4 (1983) 311-321
7. Tannock I.F., Osoba D., Stockler M.R., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14 6 (1996) 1756-1764
8. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
9. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
10. Smaletz O., Scher H.I., Small E.J., et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 20 (2002) 3972-3982
11. Halabi S., Small E., Kantoff P., et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21 (2003) 1232-1237
12. Shulman M., and Benaim E. The natural history of androgen independent prostate cancer. J Urol 172 (2004) 141-145
13. Smith M., Kabbinavar F., Saad F., et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 13 (2005) 2918-2925
14. Smith D.C., Dunn R.L., Strawderman M.S., and Pienta K.J. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 16 5 (1998) 1835-1843
15. Bubley G.J., Carducci M., Dahut W., et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17 11 (1999) 3461-3467
16. Scher H.I., Halabi S., Tannock I., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26 7 (2008) 1148-1159
17. Abal M., Andreu J.M., and Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets 3 (2003) 193-203
18. Jordan M.A., and Wilson L. Microtubules as a target for antidrugs. Nat Rev Cancer 4 (2004) 253-265
19. Haldar S., Chintapalli J., and Croce C.M. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56 (1996) 1253-1255
20. Kraus L.A., Samuel S.K., Schmid S.M., Dykes D.J., Waud W.R., and Bissery M.C. The mechanism of action of docetaxel (Taxotere) in xenograft models is not limited to bcl-2 phosphorylation. Invest New Drugs 21 3 (2003) 259-268
21. Leung S.Y., Jackson J., Miyake H., Burt H., and Gleave M.E. Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors. Prostate 44 2 (2000) 156-163
22. Leung S., Miyake H., Zellweger T., Tolcher A., and Gleave M.E. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model. Int J Cancer 91 6 (2001) 846-850
23. Tew K.D., Glusker J.P., Hartley-Asp B., Hudes G., and Speicher L.A. Preclinical and clinical perspectives on the use of estramustine as an antimitotic drug. Pharmacol Ther 56 3 (1992) 323-339
24. Kreis W., Budman D.R., and Calabro A. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br J Urol 79 (1997) 196-202
25. Chowdhury S., Burbridge S., and Harper P.G. Chemotherapy for the treatment of hormone-refractory prostate cancer. Int J Clin Pract 61 12 (2007 Dec) 2064-2070
26. Gottesman M.M., Fojo T., and Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2 (2002) 48-58
27. Kamath K., Wilson J., Cabral F., et al. BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem 280 (2005) 12902-12907
28. Di Paola R.S., and Aisner J. Overcoming bcl-2-and p53-mediated resistance in prostate cancer. Semin Oncol 26 (1999) 112-116
29. Thalasila A., Poplin E., Shih J., et al. A phase I trial of weekly paclitaxel, 13-cis-retinoic acid, and interferon alpha in patients with prostate cancer and other advanced malignancies. Cancer Chemother Pharmacol 52 (2003) 119-124
30. Tomlins S.A., Rhodes D.R., Perner S., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 (2005) 644-648
31. Mackler N.J., Pienta K.J., Dunn R.L., Cooney K.A., Redman B.G., Olson K.B., Fardig J.E., and Smith D.C. Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone sensitive prostate adenocarcinoma. Clin Genitourin Cancer 5 5 (2007) 318-322
32. Zampino M.G., Verri E., Locatelli M., et al. Vinorelbine-based chemotherapy in hormone-refractory prostate cancer. Anticancer Res 26 3B (2006) 2375-2380
33. Tester W., Ackler J., Tijani L., and Leighton J. Phase I/II study of weekly docetaxel and vinblastine in the treatment of metastatic hormone-refractory prostate carcinoma. Cancer J 12 4 (2006) 299-304
34. Oh W.K., Manola J., Babcic V., et al. Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. Urology 67 (2006) 1235-1240
35. Galsky M.D., Small E.J., Oh W.K., et al. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 23 (2005) 1439-1446
36. Rosenberg J.E., Weinberg V.K., Kelly W.K., et al. Activity of secondline chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 110 (2007) 556-563
37. Rosenber J.E., Galsky M.D., Rohs N.C., et al. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy. Cancer 106 (2006) 58-62
38. Beer T.M., Higano C.S., Saleh M., et al. Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. Invest New Drugs 25 (2007) 565-570
39. Eymard J., Oudard S., Gravis G., et al. Second-line chemotherapy with docetaxel (D) in men treated with docetaxel- based regimen for metastatic hormone-refractory prostate cancer (mHRPC). Asco Prostate Cancer Symposium (2007) (abst. 249)
40. Ross R.W., Beer T.M., Jacobus S., et al. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer 112 (2008) 521-526
41. Smith M.R., Kaufman D., Oh W., et al. Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study. Cancer 89 (2000) 1824-1828
42. Borden Jr. L.S., Clark P.E., Lovato J., et al. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer. Cancer 107 (2006) 1093-1100
43. Tester W., Ackler J., Tijani L., et al. Phase I/II study of weekly docetaxel and vinblastine in the treatment of metastatic hormone- refractory prostate carcinoma. Cancer J 12 (2006) 299-304
44. Sternberg C.N., Whelan P., Hetherington P., et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 68 (2005) 2-9
45. O'Donnell A., Judson I., Dowsett M., et al. Hormonal impact of the 17alpha-hydroxylase/C(17 20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 90 (2004) 2317-2325
46. Solit D., Ivy Sp., Kopil C., et al. Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 13 (2007) 1775-1782
47. Butler L.M., Agus D.B., Scher H.I., et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60 (2000) 5165-5170
48. 48 Wedel S.A., Sparatore A., Del Soldato P., et al. New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma. J Cell Mod Med (2008) [Epub ahead of print]
49. Duque J.L., Loughlin K.R., Adam R.M., Kantoff P.W., Zurakowski D., and Freeman M.R. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 54 (1999) 523-527
50. Di Lorenzo G., Figg W.D., Fossa S.D., et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: A Phase 2 Study. Eur Urol (2008) [Epub ahead of print]
51. Cinar B., De Benedetti A., and Freeman M.R. Post transcritpional regulation of the androgen receptor by Mammalian target of rapamycin. Cancer Res 65 (2005) 2547-2553
52. Whang Y., Wu X., Suzuki H., et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 95 (1998) 5246-5250
53. Kaper F., Dornhoefer N., and Giaccia A.J. Mutations in the PI3K/ PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions. Cancer Res 66 (2006) 1561-1569
54. Dahut W.L., Scripture C., Posadas E., et al. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 14 (2008) 209-214
55. Small E.J., Fontana J., Tannir N., et al. A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer. BJU Int 100 (2007) 765-769
56. Carducci M.A., Saad F., Abrahamsson P.A., et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 110 (2007) 1959-1966
57. Small E.J., Schelhammer P.F., Higano C.S., et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24 (2006) 3089-3094
58. Simons J.W., and Sacks N. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Urol Oncol 24 (2006) 419-424
59. Schwarz G.G. Vitamin D and the epidmiology of prostate cancer. Semin Dial 18 (2005) 276-289
60. Yang E.S., and Burnstein K.L. Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. J Biol Chem 278 (2003) 46862-46868
61. Beer T.M., Ryan C.W., Venner P.M., et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 26 (2008) 1900-1901
62. Tolcher A.W., Chi K., Kuhn J., et al. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 11 (2005) 3854-3861
63. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., and Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1597